Survodutide
SYNCHRONIZE-1
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 726
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Survodutide 3.6 mg | Obesity + T2D | 3.6 mg | 76 | ITT | -12.2% at week 76 |
| Survodutide 6.0 mg | Obesity + T2D | 6.0 mg | 76 | ITT | -13% at week 76 |
| Placebo | Obesity + T2D | n/r | 76 | ITT | -5.4% at week 76 |